Literature DB >> 3949082

Intellectual functions of patients with childhood-onset epilepsy.

E A Rodin, S Schmaltz, G Twitty.   

Abstract

The intellectual functions of 64 epileptic patients who had had an initial evaluation between five and 16 years of age, including the WISC, were re-evaluated after a period of at least five years. In general the seizure states had improved, and 50 per cent were in remission for between two and eight years. All but four were still taking at least one anticonvulsant drug. WISC IQ estimates showed a slight decrease. Verbal and performance areas could be differentially affected, and a gain in one could be offset by a loss in the other, so the Full-scale IQ might not be a reliable measure of day-to-day performance. Those whose seizures remained uncontrolled had a statistically significant decrease in performance IQ, whereas in general it was stable or increased for patients in remission. There was evidence that decreased IQ indicated slower mental growth rather than loss of previously acquired function. Phenobarbital but not phenytoin levels were inversely correlated with IQ, suggesting that the upper limit of the 'therapeutic range' of phenobarbital may already be toxic with regard to learning abilities. To optimize an epileptic child's functioning in school and to prevent long-term intellectual problems, it is advisable that IQ testing should be part of the routine initial evaluation, and that drug levels should be checked at regular intervals.

Entities:  

Mesh:

Year:  1986        PMID: 3949082     DOI: 10.1111/j.1469-8749.1986.tb03826.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  10 in total

1.  Long term effects of refractory temporal lobe epilepsy on cognitive abilities: a cross sectional study.

Authors:  H Jokeit; A Ebner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

Review 2.  Cognitive and behavioural concerns in epileptic children.

Authors:  S K Tamer
Journal:  Indian J Pediatr       Date:  1999 Nov-Dec       Impact factor: 1.967

3.  Prolonged sensory or visceral symptoms: an under-diagnosed form of non-convulsive focal (simple partial) status epilepticus.

Authors:  M Manford; S D Shorvon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-08       Impact factor: 10.154

4.  Effect of seizure control on improvement of cognitive functions in epileptic patients.

Authors:  M R Nainian; P B Behere; S Mohanti
Journal:  Indian J Psychiatry       Date:  1993-07       Impact factor: 1.759

5.  Abnormal targeting of developing hippocampal mossy fibers after epileptiform activities via L-type Ca2+ channel activation in vitro.

Authors:  Y Ikegaya
Journal:  J Neurosci       Date:  1999-01-15       Impact factor: 6.167

6.  Academic underachievement among children with epilepsy: proportion exceeding psychometric criteria for learning disability and associated risk factors.

Authors:  Philip S Fastenau; David W Dunn; Joan K Austin
Journal:  J Learn Disabil       Date:  2008 May-Jun

7.  Spine loss and other persistent alterations of hippocampal pyramidal cell dendrites in a model of early-onset epilepsy.

Authors:  M Jiang; C L Lee; K L Smith; J W Swann
Journal:  J Neurosci       Date:  1998-10-15       Impact factor: 6.167

8.  The association of MRI findings and neuropsychological functioning after the first recognized seizure.

Authors:  Anna W Byars; Ton J deGrauw; Cynthia S Johnson; Philip S Fastenau; Susan M Perkins; John C Egelhoff; Andrew Kalnin; David W Dunn; Joan K Austin
Journal:  Epilepsia       Date:  2007-04-18       Impact factor: 5.864

9.  Some antiepileptic compounds impair learning by rats in a Morris water maze.

Authors:  James D Churchill; Pei-Chun Fang; Steven E Voss; Joyce Besheer; Annette L Herron; Preston E Garraghty
Journal:  Integr Physiol Behav Sci       Date:  2003 Apr-Jun

Review 10.  Drug Treatment of Epilepsy Neuropsychiatric Comorbidities in Children.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-11-24       Impact factor: 3.022

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.